Bausch Health
Annual Report 2011

Plain-text annual report

2011 DRIVIng CHange Valeant annual Report 320815_Valeant_AnnRpt_r4.indd 2 4/18/12 11:19 AM COMPanY OVeRVIeW Valeant Pharmaceuticals International, Inc. (nYSe/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and eastern europe, Latin america, australia and South east asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWaRD-LOOkIng STaTeMenTS In addition to current and historical information, this annual Report contains forward-looking statements, including, without limitation, statements regarding our future operation and goals, our five-year strategic plan, anticipated cash flows, the growth and future development of the company and its business units, our ability to continue our performance and growth, our ability to increase sales growth or maintain market share of our products, product launches and extensions and expansion into different markets, our ability and success in integrating acquired bus nesses and/or products, our strategy regarding products and the development and approval of pipeline products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking state- ments. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements. Factors that might cause or contribute to these differences include, but are not limited to, risks and uncertainties discussed in our most recent annual or quarterly report filed with the U.S. Securities and exchange Commission, which factors are incorporated herein by reference. You should consider these in evaluating our prospects and future financial performance. These forward-looking statements are made as of the date of this report. We disclaim any obligation to update or alter these forward-looking statements in this report or the other documents to reflect actual outcomes. non-gaaP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (gaaP), the Company uses non-gaaP financial measures that exclude certain items, such as amortization of inventory step-up, stock-based compensation step-up, restructuring and acquisition-related costs, acquired in-process research and development (“IPR&D”), legal settlements, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and aSC 470-20 (FSP aPB 14-1) interest, loss on extinguishment of debt, and (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-gaaP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-gaaP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. non-gaaP financial measures are not prepared in accordance with gaaP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with gaaP. 320815_Valeant_AnnRpt_r4.indd 3 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 1 We STRIVe TO CReaTe POSITIVe CHange FOR OUR SHaReHOLDeRS, PaTIenTS, eMPLOYeeS anD CUSTOMeRS BY gROWIng OUR CURRenT PRODUCTS anD BUSIneSSeS anD COnTInUIng TO aDD TO OUR PORTFOLIO THROUgH TaRgeTeD aCQUISITIOnS In an eVeR CHangIng MaRkeTPLaCe. 320815_Valeant_AnnRpt_r4.indd 1 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 2 ReVenUe * as a result of the Biovail’s merger with Valeant, revenue reflects Biovial standalone operations as they existed prior to the completion of the merger and combined Valeant’s results only for the period subsequent to the completion of the merger on September 28, 2010. 34% We increased revenue 34% from Fourth Quarter 2010 to Fourth Quarter 2011*. 3.0 B 2.5 B 2.0 B 1.5 B 1 B 500 M $2.46 B $1.18 B $757.2 M $820.4 M 2008 2009 2010 2011 320815_Valeant_AnnRpt_r4.indd 2 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 3 1 We OPeRaTe a PORTFOLIO THaT IS DIVeRSIFIeD aCROSS geOgRaPHIC anD THeRaPeUTIC LIneS. The classic pharmaceutical strategy is to discover and develop global products by focusing on large therapeutic categories in highly populated regions such as the U.S., Western europe, Japan, India and China. at Valeant, we are focused on creating a diversified business model that includes investing in select international markets with strong growth potential, and broad product portfolios with limited patent risk. We avoid markets where there is competitive intensity from large pharmaceutical companies or areas where market growth has slowed and we have a limited ability to build scale and market presence. We believe that by targeting underserved, niche markets and compounds, Valeant can successfully execute our growth business model in the years to come and thereby create value for all our stakeholders. We concentrate on creating a diversified business model that includes investing in select markets with strong growth potential. 320815_Valeant_AnnRpt_r4.indd 3 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 4 2 We BeLIeVe SPeeD anD LaCk OF BUReaUCRaCY IS OUR gReaTeST aDVanTage. Change within the pharmaceutical industry is slow. at Valeant, we believe that by embracing a fact-based managerial process without redundant layers of decision-making, the best ideas will rapidly rise to the surface and we can make good decisions quickly. Our strategy is about being prudent: if things are working, then you invest behind them, and if they aren’t, make changes. Our employees operate within a truly low-cost environment with clear accountabilities and well-defined performance metrics. We pride ourselves on treating our financial resources as if we were owners, which of course, we are. Our employees operate within a truly low-cost environment with clear accountabilities and well-defined performance metrics. 320815_Valeant_AnnRpt_r4.indd 4 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 5 CaSH ePS * as a result of the Biovail’s merger with Valeant, Cash ePS reflects Biovial standalone operations as they existed prior to the completion of the merger and combined Valeant’s results only for the period subsequent to the completion of the merger on September 28, 2010. 88% We increased Cash ePS 88% from Fourth Quarter 2010 to Fourth Quarter 2011*. $2.93 3.0 2.5 2.0 1.5 1.0 .5 $2.29 $2.05 $1.01 2008 2009 2010 2011 320815_Valeant_AnnRpt_r4.indd 5 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 6 aDJUSTeD CaSH FLOW * as a result of the Biovail’s merger with Valeant, adjusted cash flow reflects Biovial standalone operations as they existed prior to the completion of the merger and combined Valeant’s results only for the period subsequent to the completion of the merger on September 28, 2010. 22% We increased adjusted cash flow 22% from Fourth Quarter 2010 to Fourth Quarter 2011*. 275 M 250 M 225 M $260 M $253 M $209 M $208 M 200 M $204 M 175 M 150 M 4Q 10 1Q 11 2Q 11 3Q 11 4Q 11 320815_Valeant_AnnRpt_r4.indd 6 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 7 3 We DO nOT BeT On SCIenCe, BUT On ManageMenT. In recent years, the productivity of traditional research and development has slowed, creating pressure for pharmaceutical companies to fund high-risk R&D projects in order to cover this shortfall. at Valeant, we believe in helping patients by acquiring established products that are time-tested, thereby utilizing both our scale and commercial capabilities, and our experienced management teams, to then successfully grow these products. each of our general managers is experienced at building strong businesses and bringing good products to market. We help our patients live better lives by acquiring established products that are time tested. . 320815_Valeant_AnnRpt_r4.indd 7 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 8 aCQUISITIOn TIMe LIne 2008 2009 2010 2011 2012 TRanSaCTIOn * * * ** Coria Laboratories, Ltd. DermaTech Pty Ltd. Dow Pharmaceutical Sciences, Inc. Prestwick Pharmaceuticals, Inc. * * ** ** * * * * Reckitt Benckiser (australia) Pty Limited (assets) eMO-FaRM Ltd. Tetrabenzine Wellbutrin XL Tecnofarma S.a. de C.V. Blau Farma Sp. z o.o Private Formula Holdings International Pty Limited Laboratoire Dr. Renaud * * * * * * Refissa Instituto Terapeutico Delta Ltda. Ultravate Bunker Industria Farmaceutica Ltda. Vital Science Corp. aton Pharma, Inc. Hamilton’s Suncare & Hamilton’s Skin Therapy PharmaSwiss S.a. Zovirax Cholestagel aczone ganehill Pty Limited aB Sanitas elidel / Xerese Dermik Ortho Dermatologics (assets) Zuacta afexa Life Sciences, Inc. Fleming and Company (assets) inova Probiotica Laboratorios Ltda. eyetech Inc. Pele nova Biotecnologia S.a. (Minority Interest) gerot Lannach (assets) natur Produkt International, JSC Pedinol Pharmacal, Inc. atlantis Pharma COUnTRY U.S. australia U.S. U.S. australia Poland Worldwide Rights U.S. Mexico Poland australia Canada U.S. Brazil Canada Brazil Canada U.S. australia europe U.S./Canada Canada Canada australia europe U.S./Canada/Mexico U.S./Canada U.S. Canada Canada U.S. australia Brazil U.S./Canada Brazil Russia/(CIS) Russia U.S. Mexico 320815_Valeant_AnnRpt_r4.indd 8 4/18/12 11:19 AM THeRaPeUTIC aRea DaTe annOUnCeD Dermatology Over-The-Counter/Dermatology Research and Development/Dermatology neurology/Other Over-The-Counter/Dermatology Over-The-Counter/Dermatology neurology/Other neurology/Other Branded generic Branded generic Cosmeceutical/Over-The-Counter Cosmeceutical Dermatology Dematology Dermatology/Over-The-Counter/Branded generic Branded generic/Over-The-Counter Over-The-Counter/Dermatology neurology/Orphan Drugs/Opthamology Branded generic/Over-The-Counter Branded generic/Over-The-Counter Over-The-Counter Branded generics Dermatology neurology/Other Dermatology Over-The-Counter Dermatology Dermatology Dermatology Dermatology Over-The-Counter neurology/Other Over-The-Counter Ophthalmology Biotech Branded generics Over-The-Counter Podiatry Branded generics September 08 november 08 December 08 September 08 april 09 May 09 May 09 May 09 July 09 October 09 September 09 December 09 March 10 March 10 March 10 april 10 april 10 april 10 april 10 February 11 February 11 February 11 February 11 april 11 May 11 June 11 June 11 June 11 June 11 august 11 December 11 December 11 February 12 February 12 March 12 March 12 March 12 april 12 april 12 VaLeanT annUaL RePORT 2011 9 * ** acquired by Legacy Valeant Pharmaceuticals International acquired by Legacy Biovail Corporation TRanSaCTIOn COUnTRY THeRaPeUTIC aRea DaTe annOUnCeD 2009 Reckitt Benckiser (australia) Pty Limited (assets) 2008 2010 Coria Laboratories, Ltd. DermaTech Pty Ltd. Dow Pharmaceutical Sciences, Inc. Prestwick Pharmaceuticals, Inc. eMO-FaRM Ltd. Tetrabenzine Wellbutrin XL Tecnofarma S.a. de C.V. Blau Farma Sp. z o.o Laboratoire Dr. Renaud Private Formula Holdings International Pty Limited Refissa Ultravate Instituto Terapeutico Delta Ltda. Bunker Industria Farmaceutica Ltda. Vital Science Corp. aton Pharma, Inc. Hamilton’s Suncare & Hamilton’s Skin Therapy Zovirax Cholestagel aczone ganehill Pty Limited aB Sanitas elidel / Xerese Dermik Ortho Dermatologics (assets) Zuacta inova afexa Life Sciences, Inc. Fleming and Company (assets) 2011 PharmaSwiss S.a. 2012 Probiotica Laboratorios Ltda. eyetech Inc. Pele nova Biotecnologia S.a. (Minority Interest) gerot Lannach (assets) natur Produkt International, JSC Pedinol Pharmacal, Inc. atlantis Pharma Worldwide Rights U.S. australia U.S. U.S. australia Poland U.S. Mexico Poland australia Canada U.S. Brazil Canada Brazil Canada U.S. australia europe U.S./Canada Canada Canada australia europe U.S. Canada Canada U.S. australia Brazil Brazil U.S./Canada Russia/(CIS) Russia U.S. Mexico U.S./Canada/Mexico U.S./Canada Dermatology Over-The-Counter/Dermatology Research and Development/Dermatology neurology/Other Over-The-Counter/Dermatology Over-The-Counter/Dermatology neurology/Other neurology/Other Branded generic Branded generic Cosmeceutical/Over-The-Counter Cosmeceutical Dermatology Dermatology/Over-The-Counter/Branded generic Dematology Branded generic/Over-The-Counter Over-The-Counter/Dermatology neurology/Orphan Drugs/Opthamology Over-The-Counter Branded generics Dermatology neurology/Other Dermatology Over-The-Counter Branded generic/Over-The-Counter Dermatology Dermatology Dermatology Dermatology Over-The-Counter neurology/Other Branded generic/Over-The-Counter Over-The-Counter Ophthalmology Biotech Branded generics Over-The-Counter Podiatry Branded generics September 08 november 08 December 08 September 08 april 09 May 09 May 09 May 09 July 09 October 09 September 09 December 09 March 10 March 10 March 10 april 10 april 10 april 10 april 10 February 11 February 11 February 11 February 11 april 11 May 11 June 11 June 11 June 11 June 11 august 11 December 11 December 11 February 12 February 12 March 12 March 12 March 12 april 12 april 12 320815_Valeant_AnnRpt_r4.indd 9 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 10 DeaR SHaReHOLDeR; Thank you for your interest in Valeant Pharmaceuticals International, Inc. We believe that Valeant is a unique pharmaceutical company and we are excited that you have taken the step to better understand both our strategy and operating philosophy. Valeant’s primary strategy is to leverage our speed, scale, financial strength and disciplined approach to business development to pursue substantial growth opportunities and generate long-term value for all of our shareholders. Our strategy and philosophy are both simple and powerful. They are anchored in diversified operating units led by empowered entrepreneurs – who will be rewarded for growing their businesses, their cash flows, and building leadership positions in the marketplace. Our dual engines of growth will be superior execution of well-thought-through business plans and continued new growth opportunities via disciplined acquisitions. We will do “more with less” than our competitors. Our vision for the new Valeant is to become the leading specialty pharmaceutical company in the world. We will measure our success primarily through our returns to our shareholders. We will have a balanced and diversified portfolio of businesses: in terms of types of products – branded pharmaceuticals, over-the-counter (OTC) products, branded and unbranded generics; therapeutic areas - dermatology, neurology, and ophthalmology; and geographies - U.S., Canada, Central and eastern europe, Latin america, australia, South east asia and South africa. We will measure ourselves in terms of overall growth, cash earnings, and adjusted cash flow from operations. Our portfolio will evolve and over time, we would expect to both enter and exit geographies, therapeutic areas, and potentially product forms. We will continue to seek out high- growth, high-profit markets where we expect to have a competitive advantage, and exit markets where growth and profitability are not as attractive. We also have a different approach to R&D than other pharmaceutical companies in that we don’t bet purely on science for our future growth. We like to buy in-line products that we think we can grow and take the development risk out of the equation. We prefer to access our innovation through acquiring companies and products. and where we do invest in R&D, it is primarily focused on dermatology and ophthalmology, where the risk-reward profile actually works from a standpoint of our Company’s philosophy. We also seek partners for our significant development efforts, thereby reducing our R&D expenditures as compared to our peers. While there are many remarkable pharmaceutical companies involved in discovering new compounds, overall, internal R&D for the pharmaceutical industry has not proven to be a good return for most companies over the last decade. U.S. DeRMaTOLOgY Valeant’s U.S. dermatology business continues to be a key strength and our growth further solidifies our position as a significant player in this therapeutic area. not only does dermatology have what we believe is an attractive risk and reward profile, we believe there’s room for a focused, smaller player like Valeant. We have acquired several attractive assets in the past few years that have bolstered our presence in this therapeutic class, across our geographic markets, and we will continue to look for other assets that will continue this growth. Dermik and Ortho 320815_Valeant_AnnRpt_r4.indd 10 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 11 Dermatologics are two acquisitions in 2011 that cemented our position as a leader in dermatology in the U.S. We try to avoid playing in the same areas as the big pharmaceutical companies, and focus our efforts on specialty areas like dermatology, where we can compete with a dedicated sales and marketing footprint. Our operating philosophy is based on a business model that centers on multiple, diverse products that generate between $15 million and $50 million in revenue per year. Our U.S. Dermatology segment generates product revenues from both specialty pharmaceutical and OTC products. Our principle dermatology products include: Zovirax® Ointment, Xerese®, elidel®, acanya®, atralin®, Carac®, Renova® and Retin-a Micro®, and CeraVe®. neUROLOgY anD OTHeR Our other main U.S. business segment is neurology and Other, which consists of legacy products such as Wellbutrin XL®, Xenazine® and Cardizem® CD. although demand for these products is declining, our goal is to manage this business segment to be a flat-to-slowly declining business that generates reliable cash flows for our Company. Our management approach to this portfolio, a very lean infrastructure with minimal support in non- field force promotion and targeted improvements in formulation, has worked well for these smaller specialty-focused legacy brands. Managing our neurology and Other segment to maximize our cash flows remains a key priority in 2012 and beyond. although Wellbutrin XL, Xenazine, and legacy Valeant tail products remain the largest products in this segment, we are excited to see the entry of Potiga™/ Trobalt™ into the market and believe this compound offers a unique growth opportunity. In the U.S., Potiga was approved in June 2011 and received appropriate Drug enforcement administration (Dea) scheduling in november 2011. Trobalt launched in europe in May 2011 and is now commercially available in several countries including the United kingdom, germany and Switzerland through our development partner, glaxoSmithkine. We are currently planning to launch Potiga to the U.S. market in the second quarter of 2012, again through our partner, glaxoSmithkine. as for our extended-release formulation, a lead candidate has been identified for progression into clinical evaluation. eMeRgIng MaRkeTS Our emerging Markets segment includes our historical business units in Latin america, Central and eastern europe and we recently established new growth platforms in South east asia, South africa and Russia, through several strategic transactions completed in 2011 and early 2012. Our recent acquisition of inova at the end of 2011, and our expansion into South east asia and South africa, necessitated the realignment of our segments in 2012 as we began to manage our businesses differently. We have combined our branded generics businesses in europe and Latin america, which is primarily Mexico and Brazil, into one emerging Markets segment that will also include our operations in South east asia and South africa. We view our entry into the markets of Russia, South east asia, and South africa as exciting new growth platforms and we are eager to explore these new opportunities. Our footprint is purposefully international, yet not global. We intentionally do not operate in a number of markets, such as Western europe, Japan, China and India, which are the strategic focus of other pharmaceutical companies. We continue to explore and invest in other territories that we believe are high- quality and growing and in which we believe we can achieve success with our business model. Pursuing these opportunities in the select regions that larger pharmaceutical companies are not focusing on is 320815_Valeant_AnnRpt_r4.indd 11 4/18/12 11:19 AM VaLeanT annUaL RePORT 2011 12 another key element of our operating philosophy. For example, building critical mass in Central and eastern europe was our focus in 2011, where we made two sizable acquisitions, PharmaSwiss and Sanitas, and we now operate in over 20 Central and eastern european countries primarily in branded generics and OTC products. force and a substantial presence in the weight- loss arena. We expect to continue to ramp up our efforts to create new line extensions for australia’s OTC products and hope to see regulatory approval of a few prescription products as well. Our key expectation for 2012 is to successfully integrate inova and the Valeant operations in australia. CanaDa/aUSTRaLIa Valeant is the largest multinational pharmaceutical company headquartered in Canada. Our Canadian operations are the classic specialty pharmaceutical business where most of our products are in-licensed from other companies. We continue to grow our critical mass in terms of our field force infrastructure, which allows us to call on any specialty, including primary care. This business is predominantly derived from prescription products with the largest brands consisting of Wellbutrin XL®, Cesamet® and Tiazac® XC. We are in the process of establishing a prescription dermatology business in Canada, and the acquisition of Dermik gives us a head start in this endeavor. Our OTC business in Canada is also growing and was initially built around our acquisitions of Vital Science and Laboratoire Dr. Renaud completed in 2009 and 2010, respectively. In addition, the acquisition of afexa in 2011 will add nicely to our OTC segment with the addition of the well-known COLD-FX to our portfolio. Valeant australia has primarily been an OTC business with a strong focus in dermatology. With the addition of inova in December 2011, we now have a diversified product portfolio in australia that more closely mirrors the rest of our markets. australia’s OTC business now has a leading pharmacy presence in cold and cough, a therapeutic skin-care line, and sun care, which balances out the seasonal nature of each business. The inova acquisition also brings a prescription business with a well-regarded sales LOOkIng FORWaRD at Valeant, we expect to continue our evolution into a stronger, more focused company, with our efforts positioning us to reap rewards now and in years to come. as we move forward, we will continue to pave the way for growth through the steadfast execution of our strategy that balances diverse specialties with a focused approach. We consistently look for unique opportunities in both therapeutic classes and geographic locations that other pharmaceutical companies might avoid, and we believe that the success we have achieved so far will generate more opportunities in the future. Our strong results demonstrate the strength of our base business and our ability to deliver revenue growth, earnings and cash flows. Our ability to deliver solid results is a testament to our team’s ability to effectively manage our cost structure and discover new and exciting opportunities to invest in. We hope to continue to build on our past successes and look forward to new opportunities emerging for Valeant in 2012 and beyond. Finally, I would like to personally thank Valeant’s employees and shareholders for everyone’s continued support as we work together towards building the most successful pharmaceutical company in the world. J. Michael Pearson Chairman and Chief executive Officer 320815_Valeant_AnnRpt_r4.indd 12 4/18/12 11:19 AM Board of directors J. Michael Pearson chairman and chief executive officer Valeant Pharmaceuticals international, inc. Robert A. Ingram Lead director, Valeant Pharmaceuticals international, inc. Partner, Hatteras Venture Partners committees: Nominating and corporate Governance, talent and compensation Ronald H. Farmer Managing director of Mosaic capital Partners committees: operations, talent and compensation Theo Melas-Kyriazi chief financial officer, Levitronix LLc committees: operations (chairperson), finance and transactions, audit and risk G. Mason Morfit Partner, Valueact capital committees: finance and transactions (chairperson), operations, talent and compensation Dr. Laurence E. Paul founding Principal, Laurel crown capital LLc committees: finance and transactions, operations, talent and compensation Robert N. Power corporate director committees: talent and compensation (chairperson), Nominating and corporate Governance, operations Norma A. Provencio President and owner, Provencio advisory services inc. committees: audit and risk (chairperson), special independent (chairperson), operations Lloyd M. Segal equity Partner, Persistence capital Partners committees: Nominating and corporate Governance (chairperson), finance and transactions Katharine B. Stevenson corporate director committees: audit and risk, finance and transactions, Nominating and corporate Governance . i a N r o f i L a c , a s e M a t s o c N i N a Y o t s Y B d e N G s e d i MaNaGeMeNt teaM J. Michael Pearson chairman and chief executive officer Howard B. Schiller executive Vice President and chief financial officer Rajiv De Silva President, Valeant Pharmaceuticals international, inc. and chief operating officer, specialty Pharmaceuticals Robert Chai-Onn executive Vice President, General counsel, corporate secretary and corporate Business development Brian M. Stolz executive Vice President of administration and chief Human capital officer stock excHaNGes New York stock exchange and toronto stock exchange NYse/tsx trading symbols common stock: Vrx PriNciPaL traNsfer aGeNt & reGistrar Valeant Pharmaceuticals international, inc.’s designated transfer agent is cana- dian stock transfer. the transfer agent is responsible for maintaining all records of registered stockholders (including change of address, telephone number, and name), canceling or issuing stock certificates and resolving problems related to lost, destroyed or stolen certifi- cates. if you are a registered stockholder of Valeant Pharmaceuticals international, inc. and need to change your records pertaining to stock, please contact the transfer agent listed below: Dr. Susan T. Hall, Ph.D. senior Vice President, Global Head of research and development Richard K. Masterson President and chief operating officer of Valeant international (Barbados) srL canadian stock transfer P.o. Box 700 station B Montreal, Qc H3B 3k3 canada fax: 888-249-6189 PHoNe (for all security transfer inquiries): 1-800-387-0825 or 416-682-3860 WeBsite: www.canstockta.com corPorate iNforMatioN Corporate Headquarters 4787 Levy street Montreal, Quebec H4r 2P9 canada Phone: 514.744.6792 fax: 514.744.6272 www.valeant.com iNdePeNdeNt auditors Pricewaterhousecoopers LLP iNVestor aNd Media reLatioNs You may request a copy of documents at no cost by contacting: Laurie W. Little Vice President, investor relations (949) 461-6002 ir@valeant.com email updates are also available through the investor relations page at Valeant’s website at www.valeant.com. Valeant Pharmaceuticals International, Inc. 4787 Levy Street, Montreal, Quebec H4R 2P9 Canada Phone / +1 514 744 6792 Fax / +1 514 744 6272 320815_Valeant_AnnRpt_r4.indd 1 4/18/12 11:19 AM 

Continue reading text version or see original annual report in PDF format above